Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant
Open Access
- 13 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 685176
- https://doi.org/10.3389/fphar.2021.685176
Abstract
Background: Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, may be efficacious in preserving renal function in liver transplantation (LT) recipients while preventing hepatocellular carcinoma (HCC) recurrence. Materials and Methods: In this study, we retrospectively evaluated the safety, efficacy, and renoprotective effects of mTOR inhibitors in LT recipients. Among the 84 patients enrolled, mTOR inhibitor was commenced during the first year after LT. Renal function was measured by estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease equation. Results: Regarding the type of mTOR inhibitor, everolimus was used in 71 patients and sirolimus in 13 patients. Concomitant tacrolimus was used in 63 patients (75.0%). For total enrolled patients, kidney function did not significantly change during 12 months after initiation of mTOR inhibitors, although tacrolimus-withdrawn patients (n = 21) showed better kidney function compared to tacrolimus-minimized patients (n = 63) after conversion. However, a significant improvement in kidney function was observed in the eGFR n = 19) 12 months after initiation of mTOR inhibitors, for both patient groups with early + mid starters (n = 7, stating within 1 year after LT) and late starters (n = 12, starting over 1 year after LT). mTOR inhibitors were safely administered without serious adverse events that led to drug discontinuation. Conclusion: We demonstrated that patients with renal impairment showed significant improvement in renal function regardless of the timing of mTOR inhibitor start, suggesting that switch to mTOR inhibitors may be beneficial when renal function declines.Funding Information
- National Research Foundation of Korea
This publication has 36 references indexed in Scilit:
- Sirolimus Use in Liver Transplant Recipients With Hepatocellular CarcinomaTransplantation, 2016
- Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in SpainLiver Transplantation, 2015
- Prevention and risk factors of hepatitis B recurrence after living donor liver transplantationJournal of Gastroenterology and Hepatology, 2013
- Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled TrialAmerican Journal of Transplantation, 2012
- Surgical Outcome of Right Liver Donors in Living Donor Liver Transplantation: Single-Center Experience with 500 CasesJournal of Gastrointestinal Surgery, 2012
- Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysisLiver Transplantation, 2011
- Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trialLiver Transplantation, 2009
- Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin InhibitorsAnnals of Surgery, 2008
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Banff schema for grading liver allograft rejection: An international consensus documentJournal of Hepatology, 1997